Anti-cancer drug safe and effective for treating light chain (AL) amyloidosis
There's a new treatment option available for patients with AL amyloidosis: daratumumab.
Jan 27, 2020
0
10
There's a new treatment option available for patients with AL amyloidosis: daratumumab.
Jan 27, 2020
0
10
A collaboration led by scientists at Tokyo University of Agriculture and Technology (TUAT), Japan, has discovered a novel amyloid protein that induces amyloidosis in rats. This new amyloid protein is known to be the lipopolysaccharide ...
Oct 25, 2019
0
5
A new staging system developed with a more accessible test to predict the chance of survival in patients living with light chain (AL) amyloidosis. Led by researchers from the Amyloidosis Center at Boston Medical Center (BMC) ...
Nov 7, 2018
0
0
Researchers at Boston Medical Center (BMC) have reported that a new heart imaging test can determine whether cardiac amyloidosis patients are expected to survive after a stem cell transplant. They accomplished this by analyzing ...
Dec 12, 2016
0
0
Two new treatments are showing promise and overall survival is on the rise for AL amyloidosis, according to a series of studies involving researchers in the Abramson Cancer Center and the Perelman School of Medicine at the ...
Dec 1, 2016
0
0
(HealthDay)—For patients with heart failure due to light-chain amyloidosis (AL), three-drug therapy with bortezomib, dexamethasone, and an alkylating agent (BDex+AA) is associated with improved survival, according to a ...
Jun 21, 2016
0
34
Patients with Light-chain (AL) amyloidosis who are treated with high-dose chemotherapy (melphalan) and autologous (one's own) stem cell transplantation (HDM/SCT) have the greatest success for long-term survival.
Oct 8, 2015
0
5
(HealthDay)—Increased serum free light chains (FLCs) precede the presentation of immunoglobulin light chain amyloidosis (AL amyloidosis), according to a study published online July 14 in the Journal of Clinical Oncology.
Jul 25, 2014
0
0
Researchers from Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) have generated the first known disease-specific induced pluripotent stem cell (iPSC) lines from a patient with familial transthyretin ...
Oct 31, 2013
0
0
(Medical Xpress)—An international team of researchers has discovered a way to silence the genes that cause transthyretin amyloidosis—a fatal genetic disease. In their paper published in the New England Journal of Medicine, ...